# Rett syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/rett-syndrome

> 2 upcoming FDA catalysts in Rett syndrome: NGN-401 (NGNE) on December 2029 (primary completion); NGN-401 (NGNE) on Dec 2029 to Mar 2030 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2023 | [DAYBUE (trofinetide) FDA approval](https://sec-api.dev/pdufa/trofinetide) | ACAD | Rett syndrome | completed, approved | "In March 2023, the FDA approved the Company's second drug, DAYBUE® (trofinetide), for the treatment of Rett syndrome." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000119312526447794/acad-20260930.htm)) |
| November 6, 2025 | [Syndrome trial start](https://sec-api.dev/pdufa/syndrome) | NGNE | Rett syndrome | completed | "NEW YORK - November 6, 2025 - Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000091/ngne_prxdosedfirstparticip.htm)) |
| Dec 2025 | [DAYBUE (trofinetide) FDA approval](https://sec-api.dev/pdufa/trofinetide) | ACAD | Rett syndrome | completed, approved | "The FDA approved DAYBUE STIX in December 2025 for the treatment of Rett syndrome and we made the product available on a limited basis in the first quarter of 2026 followed by a broader launch in the second quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000119312526447794/acad-20260930.htm)) |
| December 2029 | [NGN-401 primary completion](https://sec-api.dev/pdufa/ngn-401) | NGNE | Rett Syndrome | scheduled | "NCT05898620 (A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Neurogene Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05898620)) |
| Dec 2029 to Mar 2030 | [NGN-401 topline data readout](https://sec-api.dev/pdufa/ngn-401) | NGNE | Rett Syndrome | scheduled | "NCT05898620 (A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Neurogene Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05898620)) |

## Drugs

- [DAYBUE (trofinetide)](https://sec-api.dev/pdufa/trofinetide) (ACAD)
- [Syndrome](https://sec-api.dev/pdufa/syndrome) (NGNE)
- [NGN-401](https://sec-api.dev/pdufa/ngn-401) (NGNE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/rett-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Rett syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/rett-syndrome

```bibtex
@misc{secapidev_indications_rett_syndrome_20261116,
  title        = {Rett syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/rett-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_rett_syndrome_20261116","title":"Rett syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/rett-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
